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T‑cadherin deficiency increases vascular
vulnerability in T2DM through impaired NO
bioactivity
Han Wang1,2†, Ling Tao1*, Anastasia Ambrosio2†, Wenjun Yan1, Ross Summer3, Wayne Bond Lau2, Yajing Wang2
and Xinliang Ma2*

Abstract
Background: Endothelial dysfunction plays a critical role in the development of type 2 diabetes (T2DM). T-cadherin
(T-cad) has gained recognition as a regulator of endothelial cell (EC) function. The present study examined whether
T-cad deficiency increases vascular vulnerability in T2DM.
Methods: Vascular segments were isolated from WT or T-cad knockout mice. Endothelial function, total NO accumulation, and the expression of T-cad related proteins were determined.
Results: Ach and acidified NaNO2 induced similar vasorelaxation in WT groups. T-cad KO mice exhibited normal response to acidified NaNO2, but manifested markedly reduced response to Ach. NO accumulation was also
decreased in T-cad KO group. T-cad expression was reduced in WT mice fed 8 weeks of high fat diet (HFD). Furthermore, exacerbated reduction of vasorelaxation was observed in T-cad KO mice fed 8 weeks of HFD.
Conclusions: In the current study, we provide the first in vivo evidence that T-cadherin deficiency causes endothelial
dysfunction in T2DM vascular segments, suggesting the involvement of T-cad deficiency in T2DM pathogenesis.
Keywords: Endothelial cell, Endothelial dysfunction, T-cadherin, T2DM, NO bioactivity, Vascular ring
Background
Type 2 diabetes mellitus (T2DM) affects approximately
100 million people worldwide [1]. Diabetic vascular complications are responsible for the majority of morbidity
and mortality in the diabetic population. These complications can be arbitrarily divided into micro- and macrovascular complications. Macrovascular complications
are associated with accelerated atherosclerosis, resulting
in premature ischemic heart disease, increased risk of
cerebrovascular disease, and severe peripheral vascular
disease [2].
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Endothelial dysfunction is characterized by deficiency
of nitric oxide (NO) production in response to normal
secretion signals. A critical component of atherosclerosis
development, endothelial dysfunction is a characteristic
abnormality observed in diabetes [3–5]. The bioavailability of NO, produced by endothelial NO synthase (eNOS),
represents a key marker of vascular health. Down-regulated NO may contribute to atherogenic predisposition.
Many metabolic derangement factors cause endothelial
dysfunction by affecting the balance of NO production
during diabetes development [6–8]. Therefore, clarification of the mechanisms responsible for endothelial dysfunction in diabetes, and identification of the therapeutic
interventions that may improve endothelial function hold
great potential in reducing cardiovascular complications
and overall death in diabetic patients.
T-cadherin (T-cad) is a unique member of the cadherin family. Found on the cellular surface, it possesses
no intracellular domain. T-cadherin content is maximal
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in the aorta, carotid, iliac, and renal arteries, and in the
heart. Known to regulate neuronal growth during embryogenesis, T-cad has additionally gained recognition as a
regulator of endothelial cell (EC) function [9–11].
In vivo expression of T-cad is increased in human
atherosclerotic lesions and experimental restenosis.
In vitro expression of T-cad is upregulated in proliferating endothelial and smooth muscle cells, as well
as endothelial cells during oxidative and endoplasmic
reticulum stress [11, 12]. Clinical evidence underlines
the association between T-cad and hypoadiponectinemia, with increased risk of various metabolic diseases
[13, 14]. Together, these observations strongly suggest
the involvement of T-cad in diabetic vasculopathic state
development. However, direct evidence that supported
T-cadherin deficiency exists in diabetic endothelial dysfunction pathogenesis is currently lacking.
Therefore, the aims of the present study were: (1) to
determine whether T-cad deficiency is involved in the
development of T2DM, (2) to determine whether T-cad
deficiency may cause endothelial dysfunction in descending aortic vascular segments (the most frequent location of atherosclerosis development), (3) to determine
whether endothelial dysfunction is exacerbated by T-cad
deficiency in descending aortic vascular segments in
T2DM, and (4) to elucidate the responsible underlying
mechanisms.

Methods
Determination of vasorelaxation in aortic tissue

Adult male T-cad knockout mice (T-cad KO) or their
wild type littermates (WT) were used in all study experiments. All experiments were performed in adherence to
the NIH Guidelines on the Use of Laboratory Animals,
and approved by the Thomas Jefferson University Committee on Animal Care. After animals were anesthetized
with 3% isoflurane, descending aortas were removed and
placed into cold Krebs buffer solution [NaCl 118, KCl
4.75, CaCl2·2H2O 2.54, KH2PO4 1.19, MgSO4·7H2O 1.19,
NaHCO3 25, and glucose 10.0 (mM)] Aorta were carefully cut into 2–3 segments (each 2–3 mm length); surrounding fat and tissue were debrided. Segments were
suspended upon stainless steel hooks, and aerated (95%
O2 and 5% CO2) in 37 °C 5 ml K–H tissue baths. Aortic rings were connected to FORT-10 force transducers
(WPI, Sarasota, FL) for MacLab data acquisition. Segments were first stretched to generate 2.5 mN force, followed by 0.5 mN increments every 15 min until achieving
4 mN total force. As force was increased to 8mN, the
Krebs buffer solution was replaced with a buffer with
increased potassium content (HK solution) for vessel
ring sustainability. Once 8 mN force was achieved, the
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tissue bath was replaced with normal Krebs buffer. During the period of force decrease from 8 to 4 mN, epinephrine (a potent vasoconstrictor) was added to the tissue
bath in 2 concentrations (10−5 and 10−4 M) in sequence
within 2 min of each other, to induce vasoconstriction.
After ~5 min, the vasorelaxant acetylcholine (concentrations of 10−6, 10−5, 10−4, 10−3 and 10−2 M) were added
to the tissue bath in immediate succession. The percent
relaxation from the peak of the epinephrine-induced
contraction to the nadir point of acetylcholine-induced
relaxation was recorded on MacLab.
Determination of NO accumulation from aortic segments

To determine total NO accumulation, isolated aortic segments were placed in culture medium and incubated in a
cell culture incubator (5% CO2, 37 °C). After 8 h of incubation, segments were subjected to homogenization. Protein concentrations were determined via BCA method
(Pierce Chemical). Medium was transferred into the wells
of 96-well plate, and incubated with nitrate reductase
and cofactors for 20 min at 37 °C to reduce NO3 to NO2.
Samples (50 μl) were then injected into a water-jacketed,
oxygen-free purge vessel containing 5 ml of 20 mM
potassium iodide in glacial acetic acid to reduce NO2 to
NO. Resultant chemiluminescence from the reaction of
NO and ozone was detected by a nitric oxide analyzer
(SIEVERS NOA 280I; Sievers, Boulder, CO). Detector
signals were collected and analyzed by a PC-based data
recording and processing system. To determine the NO
content of the culture medium, calculations of the slope
of the regression analysis were performed. The amount of
NOx released was expressed in nmol/mg protein.
Determination of NOx production from aortic segments

To detect endothelial NOx production, isolated aortic
segments were placed in 6-well plates with 500 μl culture medium. Epinephrine (10−4 M) was added to each
well. 3 min later, acetylcholine concentrations (10−6,
10−5, 10−4, 10−3 and 10−2 M) were added in immediate
succession. Resultant medium nitrite (NO2−) and nitrate
(NO3−) levels were determined by chemiluminescence
NO detector (Siever 280i NO Analyzer).
Quantitation of tissue nitrotyrosine content

Nitrotyrosine content, the accepted footprint of in vivo
peroxynitrite (ONOO−) formation, was determined by
ELISA described in our previous publication [15]. In
brief, aortic segments were homogenized in lysis buffer
and centrifuged for 10 min at 12,000g at 4 °C. Supernatants were collected and protein concentrations were
determined. Tissue samples from aortic segments, were
applied to disposable sterile ELISA plates, and incubated
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overnight with primary antibody against nitrotyrosine (05–233, Millipore, USA). After extensive wash and
incubation with the peroxidase-conjugated secondary
antibody, the peroxidase reaction product was generated
using TMB solution. The optical density was measured at
450 nm with a SpectraMax-Plus microplate spectrophotometer. The amount of nitrotyrosine content in tissue
samples was calculated using standard curves generated
from nitrated BSA containing known amounts of nitrotyrosine, and expressed as pmol/mg protein.

Results

Immunoblotting

T‑cad deficiency induced endothelial dysfunction

Aortic tissue homogenate proteins were separated on
SDS-PAGE gels, transferred to PVDF membranes, and
Western blotted with monoclonal antibody against
eNOS, Ser1177 phosphorylated eNOS (Becton–Dickinson, USA), and polyclonal antibody against Akt and
Ser473 phosphorylated Akt (Cell Signaling Technology,
USA). PVDF membranes were incubated with horseradish peroxide-conjugated anti-rabbit or anti-mouse IgG
antibodies (Cell Signaling Technology, USA) for 2 h. The
blot was developed using Super-Signal Reagent (Pierce)
and visualized with a Kodak Image Station 4000R. Blot
densities were analyzed (Gelpro32 software).
Real‑time PCR

Total RNA was extracted from aortic segments via RNeasy Mini Kit (QIAGEN, USA). Expression analysis of
the reported genes was performed by real-time PCR
via commercial kit (4367659, AB) and the ABI 7500
Sequence Detection System, using SYBR GREEN as a
double-stranded DNA-specific dye. GAPDH served as
endogenous control. Table 1 lists the primers for mRNA
expression analysis by real-time PCR.
Statistical analysis

All values in the text, table, and figures are presented
as mean ± SEM of n independent experiments. Data
(except Western blot density) were subjected to t test
(two groups) or ANOVA (three or more groups) followed
by Bonferoni correction for post hoc t test. Western blot
densities were analyzed by the Kruskal–Wallis test followed by Dunn’s post test. Probabilities of 0.05 or less
were considered to be statistically significant.
Table 1 Primers sequences for Real-time PCR analysis
Genes

Primers

GAPDH-F (mouse)

5′-AGGTCGGTGTGAACGGATTTG-3′

GAPDH-R (mouse)

5′-TGTAGACCATGTAGTTGAGGTCA-3′

T-cad-F (mouse)

5′-CATCGAAGCTCAAGATATGG-3′

T-cad-R (mouse)

5′-GATTTCCATTGATGATGGTG-3′

T‑cad mRNA and protein expression decreased in WT mice
fed 8 weeks HFD

We first determined T-cad expression during T2DM
condition. In an established diet-induced T2DM model,
we fed WT mice high fat diet for 8 weeks, and determined both the mRNA and protein levels of T-cadherin
[16]. Both mRNA and protein levels of T-cadherin were
reduced compared to control, suggesting T-cadherin
deficiency occurs during type 2 diabetes (Fig. 1).
We next performed a vascular ring experiment to directly
address this relationship. In WT aortic rings, administration of Ach (an endothelial-dependent NO donor)
resulted in concentration-dependent vasorelaxation, with
no significant difference compared to the effects elicited
by acidified NaNO2 (an endothelial-independent NO
donor). At maximal concentration (100 μM), Ach and
acidified NaNO2 induced 79.7 and 85.9% vasorelaxation respectively, demonstrating preserved vascular ring
endothelial function post-preparation protocols. However, aortic rings from T-cad KO mice exhibited markedly
reduced vasorelaxation by Ach (endothelial-dependent
stimulation) treatment compared to that induced by acidified NaNO2 (endothelial-independent NO donor) treatment. Furthermore, addition of 100 μM Ach resulted in
only 54.5% relaxation (P < 0.01 vs. WT) in T-cad KO aortic ring; 100 μM acidified NaNO2 induced 82.3% relaxation (P > 0.05 vs. WT) (Fig. 2). Together, these results
demonstrate T-cad deficiency resulted in severe endothelial dysfunction in the tested aortic segments.
T‑cad deficiency‑induced endothelial dysfunction
exacerbated in T2DM

The above experiments verified T-cad deficiency occurs
in T2DM, and T-cad deficiency was associated with vascular segment endothelial dysfunction. Next, we determined the state of endothelial function in T-cad KO
animals under in-viro or in vivo diabetic environment.
We first utilized an in vitro model of diabetes, employing
high glucose (HG, 25.5 mmol/l), high fat (HF, palmitate
300 μmol/l) treatment. After incubating aortic rings from
WT and T-cad KO mice in HGHF (2.5 h), vasorelaxation
was impaired in both animal types. However, the reduction in concentration-dependent vasorelaxation was
markedly increased in T-cad KO mice compared to WT.
To better mimic in vivo T2DM, we next fed WT mice
and T-cad KO mice 8 weeks of HFD diet as previously
described [17]. Again, ring vasorelaxation was reduced in
both WT and T-cad KO mice. Vasorelaxation reduction
was more pronounced in T-cad KO mice compared to
WT mice (Fig. 3). Collectively, these results suggest that
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Fig. 1 T-cad mRNA and protein expression were reduced in WT mice fed 8 weeks HFD. T-cad expression as measured by Western blot and real time
PCR a representative Western blots; b Western blot density analysis (n = 4); c Real time PCR analysis (n = 3).**P < 0.01 vs. WT
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Fig. 2 T-cad deficiency induced endothelial dysfunction. Concentration-dependent vasorelaxation of aortic vascular rings in response to a Ach, an
endothelium-dependent vasodilator, and b acidified NaNO2, an endothelium-independent vasodilator. Top representative figures; Bottom analysis
result. Each mouse aorta generated 2–3 rings, n = 8–12 rings/group. WT wild type litternates, T-cad KO T-cadherin knockout mice. *P < 0.05 vs. WT
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Fig. 3 T-cad deficiency induced-endothelial dysfunction was exacerbated in T2DM. Concentration-dependent vasorelaxation of aortic vascular
rings subjected to a high glucose/high fat treatment (high glucose: 25.5 m mol/l; high fat/palmitate: 300 μ mol/l) and b high fat diet alone for
8 weeks. Top representative figures; Bottom analysis result. Each mouse aorta generated 2–3 rings, n = 6–7 rings/group. WT Wild type litternates,
T-cad KO T-cadherin knockout mice. **P < 0.01 vs. WT

endothelial dysfunction caused by T-cad deficiency was
exacerbated in the T2DM condition.
Total NO accumulation and NOX production significantly
decreased in vascular segments from T‑cad KO animals

Next, total NO accumulation and NOx production were
determined. Aortic segments were isolated from WT
and T-cad KO animals, and incubated with cell culture
medium. Culture media was collected after 8 h. Total NO
accumulation in aortic segments from T-cad KO mice
was significantly decreased compared to WT (Fig. 4). To
measure direct NO release after Ach stimulation, total
NOx production was determined. As expected, total NOx
production was markedly decreased in T-cad KO mice
compared to WT. Together, these results demonstrate
that T-cad deficiency was associated with reduced NO
production, which may be responsible in part for the
observed state of endothelial dysfunction.

(not to significant degree) compared to WT. These results
suggest that reduction of NO bioavailability caused by
T-cad deficiency may induce phosphorylation of the AkteNOS pathways in compensatory manner, without significant effect.
Akt inactivation increases caspase‑3 activity in HUVECs

To further investigate the contributive mechanisms
of reduced NO bioactivity, we cultured and subjected
human umbilical vein endothelial cells (HUVECs) to Akt
inhibitor (A6730, Sigma, (10 μM) treatment for 24 h.
Akt phosphorylation and caspase-3 activity were determined. Akt phosphorylation was significantly decreased,
whereas caspase-3 activity was elevated in HUVECs subjected to Akt inhibitor treatment compared to control
(Fig. 6). These results strongly suggest Akt inhibitioninduced endothelial cell apoptosis contributes to reduced
NO bioactivity in T-cad KO aortic tissue.

Phosphorylation of Akt, but not eNOS, was significantly
reduced in T‑cad KO aortic tissue

Increased nitric oxide inactivation exacerbated endothelial
dysfunction in T‑cad KO mice

To study the underlying mechanisms, we performed
Western blot. Akt phosphorylation was significantly
increased in T-cad KO mice compared to WT (Fig. 5),
consistent with known current research. However, eNOS
phosphorylation in T-cad KO mice was slightly increased

We next determined whether the endothelial dysfunction observed in T-cad deficient animals is related to
increased superoxide production and nitric oxide inactivation. Tissue nitrotyrosine level was determined, the
accepted in vivo footprint of peroxynitrite (ONOO−), the
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Fig. 4 Basal NO production was significantly decreased in vascular segments from T-cad deficient animals. a NO concentration in culture medium
after 8 h incubation of aortic segments from WT or T-cadherin knockout mice. b Concentration of nitric oxide in medium after Ach stimulation. Each
mouse aorta generated 2 aortic segments. n = 8 segments/group. *P < 0.05 vs. WT
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Fig. 5 Phosphorylation of Akt, but not eNOS, was significantly reduced in aortic tissue from T-cad KO animals. Expression of Akt, p-Akt, eNOS and
p-eNOS in aortic tissues obtained from WT or T-cadherin knockout mice. Left representative Western blots. Right summary of density analysis of
p-Akt/Akt (a) and p-eNOS/eNOS (b), n = 3 mice/group, *P < 0.05 vs. WT

product of NO and superoxide. Superoxide production
was markedly increased in T-cad KO animals, and nitrotyrosine was significantly increased in T-cad KO mice

compared to WT (Fig. 7). These results support augmented NO inactivation as a primary cause of endothelial dysfunction in T-cad deficient animals.
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Fig. 7 Increased nitric oxide inactivation exacerbated endothelial dysfunction in T-cad KO mice. a Aortic nitrotyrosine content determined by
ELISA; b quantitative assay of superoxide production determined by lucigenin-enhanced chemiluminescence, n = 3–4 mice/group, *P < 0.05 vs.
WT, **P < 0.01 vs. WT

Discussion
Adiponectin (APN) is a multifunctional adipocytokine
of adipose tissue origin. APN exists in three isoforms
(trimer, hexamer, and multimer). Plasma APN concentration (which consists of mostly the latter two high
molecular weight isoforms) highly correlates with the
development of T2DM. Numerous studies have shown
that plasma adiponectin level is decreased in individuals with T2DM, indicating APN plays an important
role in pathogenesis of T2DM [18–20]. T-cad has been
identified as an important receptor of APN, particularly
for the high molecular weight isoform [21–24]. Both
plasma APN concentration and tissue APN expression
are closely related with T-cad [14]. Additionally, T-cad

itself is implicated with the pathogenesis of T2DM, but
with uncertain role [25, 26]. In the present study, we have
provided the first in vivo evidence that T-cad expression
is decreased in the aorta from T2DM animals (Fig. 1).
This data is consistent with Matsuda’s study demonstrating T-cad expression is positively correlated with plasma
APN concentration, which is markedly decreased in
T2DM patients [14].
Atherosclerosis is the basis for the vascular pathologies
of T2DM. Endothelial dysfunction plays a key role in this
process, and the ongoing underlying mechanisms [27–
29]. Many studies have demonstrated T-cad plays a central multifunctional role in the vascular system [30–34].
Heretofore, no direct in vivo functional evidence exists
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demonstrating the role T-cad plays in endothelial dysfunction. We next performed a vascular ring experiment
to study the relationship between T-cad and endothelial dysfunction. Our results demonstrated significantly
reduced vasorelaxation in T-cad KO mice compared to
WT, consistent with numerous in vitro studies (Fig. 2)
[35, 36], suggesting T-cad deficiency may cause severe
endothelial dysfunction. To investigate whether T2DM
exacerbates endothelial dysfunction already caused by
T-cad deficiency, we fed mice high-fat diet for 8 weeks to
mimic T2DM. Our resultant data provide the first in vivo
functional evidence T-cad deficiency exacerbates severe
endothelial dysfunction in the T2DM condition (Fig. 3).
NO, produced by eNOS, is a critical vasodilator in the
vascular system. NO bioavailability is a surrogate marker
of endothelial cell function. To obtain further evidence
supporting endothelial dysfunction occurs in T-cad KO
vascular segments, we next performed total NO accumulation and NOx production. Our results confirmed that
NO production and NOx production were both reduced
in T-cad deficient animals (Fig. 4), suggesting T-cad deficiency was associated with reduced NO production,
which may be responsible in part for the observed state
of endothelial dysfunction.
Interestingly, phosphorylation of Akt was significantly
decreased in T-cad KO animals, while phosphorylation of
eNOS was grossly unchanged compared to WT (Fig. 5).
At the beginning, we thought this reduction in Akt phosphorylation may induce the reduction in eNOS phosphorylation, which is a classical factor to mediate NO
production [37]. But our eNOS results, which are consistent with the data of others, did not support this hypothesis
[9]. The PI3 k/Akt pathway is highly associated with apoptosis [38]. The reduction in Akt phosphorylation may be
contributive to apoptosis induction in EC, which partially
explains why NO and NOx production were reduced in
EC in vascular segments in T-cad KO mice. Therefore, we
utilized Akt inhibitor to attenuate Akt phosphorylation
and found caspase-3 activity was significantly increased in
HUVECs subjected to Akt inhibitor (Fig. 6). Collectively,
our results, which is consistent with the data of others [9,
35], suggested Akt inhibition induced apoptosis, but not
reduced eNOS phosphorylation, contributes to decreased
NOx production in ECs. Further studies directly addressing this phenomenon are expected.
Experimental and clinical data have demonstrated augmented superoxide production and the resultant superoxide/nitric oxide bi-radical reaction is the primary
cause for NO inactivation under pathological conditions.
Newly produced NO is oxidized to NO2− and NO3− rapidly under physiological conditions, reducing NO bioavailability and its vasorelaxative potential, termed NO
inactivation. In the presence of superoxide, NO forms
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peroxynitrite (ONOO−), a toxic molecule that modifies tyrosine residues in proteins to create nitrotyrosine,
leaving a footprint detectable in vivo [39]. In our present
study, we have demonstrated both increased superoxide
and nitrotyrosine content in T-cad KO animals (Fig. 7).

Conclusions
We have provided the first in vivo evidence that T-cad
deficiency causes endothelial dysfunction in T2DM
model vascular segments, supporting T-cad deficiency
involvement in the pathogenesis of T2DM complications.
Supplanting T-cad deficiency may be a potential therapeutic avenue in the prevention and amelioration of vascular injury in the diabetic population.
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